MCO:NYSE
Moody's Corporation
Data as of 2026-03-10 - not real-time
$462.69
Latest Price
7/10Risk
Risk Level: Medium
Executive Summary
Moody's posted a solid Q4 2025 performance, beating EPS expectations and delivering double‑digit revenue growth to a strong multi‑billion level. The company’s profit margins remain robust—gross margin near three‑quarters, operating margin over 40% and net profit margin exceeding 30%—and its return on equity is an eye‑catching 60% plus. Cash flow is healthy, generating strong operating and free cash, while the dividend payout sits at a modest 27% of earnings, supporting a sub‑1% yield. However, the balance sheet is levered, with total debt more than three times cash, and the market is pricing the stock at a forward PE well above the industry average, indicating significant overvaluation.
On the price side, the shares trade above the short‑term moving average but below the longer‑term averages, signaling a short‑term bearish bias, while the MACD histogram has turned positive, hinting at a possible technical bounce. Volatility remains high and beta is above one, adding to market risk, and trading volume is on a downtrend. Analyst consensus remains bullish with a median price target well above the current level, implying upside potential. Given the strong fundamentals but stretched valuation and elevated risk profile, the short‑term view is neutral, the medium‑term stance is cautious, and the long‑term outlook remains positive for investors willing to endure near‑term price corrections.
On the price side, the shares trade above the short‑term moving average but below the longer‑term averages, signaling a short‑term bearish bias, while the MACD histogram has turned positive, hinting at a possible technical bounce. Volatility remains high and beta is above one, adding to market risk, and trading volume is on a downtrend. Analyst consensus remains bullish with a median price target well above the current level, implying upside potential. Given the strong fundamentals but stretched valuation and elevated risk profile, the short‑term view is neutral, the medium‑term stance is cautious, and the long‑term outlook remains positive for investors willing to endure near‑term price corrections.
Trading Recommendations
Short Term
< 1 yearhold
Conviction: 6/10
Key Factors
- price below longer‑term moving averages indicating bearish bias
- recent earnings beat supports near‑term stability
- valuation remains well above fair value limits upside
Medium Term
1–3 yearshold
Conviction: 7/10
Key Factors
- sustained revenue and margin expansion
- elevated debt load raises financial risk
- valuation still stretched relative to fundamentals
Long Term
> 3 yearsbuy
Conviction: 8/10
Key Factors
- high ROE and strong cash generation provide durable earnings power
- dividend payout is low and sustainable
- global risk‑assessment franchise offers a durable competitive moat
Key Metrics & Analysis
Financial Health
Revenue Growth13.00%
Profit Margin31.86%
P/E Ratio33.8
ROE62.08%
ROA13.83%
Debt/Equity176.81
P/B Ratio20.3
Op. Cash Flow$2.9B
Free Cash Flow$2.1B
Industry P/E17.4
Technical Analysis
TrendBearish
RSI47.4
Support$402.28
Resistance$483.92
MA 20$450.48
MA 50$489.56
MA 200$491.77
MACDBullish
VolumeDecreasing
Fear & Greed Index75.89
Valuation
Fair Value$249.15
Target Price$546.70
Upside/Downside18.16%
GradeOvervalued
TypeGrowth
Dividend Yield0.87%
Risk Assessment
Beta1.03
Volatility45.51%
Sector RiskMedium
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
More Tickers
This analysis may contain inaccuracies. Not financial advice. Always do your own research before making any investment decisions.